Letters to the Editor
Vol. 18 No. 2 (2026)
https://doi.org/10.4081/dr.2025.10237

Primary cutaneous marginal zone lymphoma in a patient with multiple sclerosis under fingolimod therapy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 24 December 2024
Accepted: 17 May 2025
Published: 11 July 2025
411
Views
295
Downloads
7
HTML
Lymphoma, B cell lymphoma, fingolimod, sphingosine-1-phosphate receptor antagonist, T cell lymphoma

Authors

Thilo Gambichler
t.gambichler@klinikum-bochum.de
Department of Dermatology, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund; Department of Dermatology, Christian Hospital, Unna; Department of Dermatology, Ruhr-University Bochum, Germany.
Sera Selina Weyer-Fahlbusch
Department of Dermatology, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund, Germany.
Markus Werner
Department of Dermatology, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund, Germany.
Ulrika Schade
Hematopathology Lübeck Center, Germany.
Lieselotte Bissels
Department of Neurology, Dortmund Hospital gGmbH, Witten-Herdecke University, Dortmund, Germany.
Laura Susok
Department of Dermatology, Christian Hospital, Unna, Germany.

Dear Editor,

Increased prevalence of cancer, in particular lymphomas, has been observed in patients with multiple sclerosis (MS) treated with fingolimod. We report the first case of primary cutaneous marginal zone lymphoma (PCMZL) that developed under longterm fingolimod therapy for MS. [...]

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Askari M, Mirmosayyeb O, Ghaffary EM, et al. Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis. Mult Scler Relat Disord 2022;59:103680.
2. Wills A, Fan G, Kim E, et al. Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod. Dermatol Online J 2019;25:13030/qt2g62q2fq.
3. Connolly A, Grandi V, Stefanato CM, et al. Primary cutaneous CD30+ anaplastic large-cell lymphoma associated with fingolimod. Br J Dermatol 2018;179:1400-1.
4. Froehlich A, Schmidt S, Landsberg J, et al. Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod. Mult Scler 2018;24:1785-7.
5. Soma L, Crisan L, Reid J, et al. Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature. Am J Clin Pathol 2024:aqae124.
6. Stitt DW, Boes CJ, Flanagan EP, et al. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler Relat Disord 2018;19:115-7.
7. Awada Z, Hameed N, Harel A. Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Des Devel Ther 2024;18:5985-96.

How to Cite



1.
Gambichler T, Weyer-Fahlbusch SS, Werner M, Schade U, Bissels L, Susok L. Primary cutaneous marginal zone lymphoma in a patient with multiple sclerosis under fingolimod therapy. Dermatol Reports [Internet]. 2025 Jul. 11 [cited 2026 Aug. 8];18(2). Available from: https://journals.pagepress.net/dr/article/view/10237
Copyright (c) 2025 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.